NYSE · ADCT
Healthcare · Biotechnology
$1.10
Up+$0.09 (+8.91%)
Updated Aug 18, 2026, 1:23 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ADCT closed at $1.10 after 21 trading sessions, down 12.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 17, 2026 | $0.99 | $1.10 | $0.95 | $1.10 | 3.73M |
| Aug 14, 2026 | $1.02 | $1.04 | $1.00 | $1.01 | 1.35M |
| Aug 13, 2026 | $1.07 | $1.10 | $0.9393 | $1.05 | 2.19M |
| Aug 12, 2026 | $1.20 | $1.23 | $1.155 | $1.23 | 563.56K |
| Aug 11, 2026 | $1.11 | $1.20 | $1.11 | $1.18 | 664.34K |
| Aug 10, 2026 | $1.14 | $1.17 | $1.12 | $1.13 | 569.55K |
| Aug 7, 2026 | $1.08 | $1.17 | $1.08 | $1.13 | 534.56K |
| Aug 6, 2026 | $1.07 | $1.13 | $1.07 | $1.13 | 722.74K |
| Aug 5, 2026 | $1.11 | $1.15 | $1.07 | $1.07 | 971.14K |
| Aug 4, 2026 | $1.05 | $1.12 | $1.04 | $1.10 | 1.37M |
| Aug 3, 2026 | $1.07 | $1.08 | $1.03 | $1.05 | 866.39K |
| Jul 31, 2026 | $1.11 | $1.12 | $1.045 | $1.05 | 757.73K |
| Jul 30, 2026 | $1.09 | $1.13 | $1.07 | $1.11 | 887.74K |
| Jul 29, 2026 | $1.10 | $1.125 | $1.0712 | $1.10 | 924.5K |
| Jul 28, 2026 | $1.14 | $1.151 | $1.10 | $1.11 | 747.77K |
| Jul 27, 2026 | $1.18 | $1.21 | $1.12 | $1.14 | 787.75K |
| Jul 24, 2026 | $1.25 | $1.26 | $1.145 | $1.15 | 725.75K |
| Jul 23, 2026 | $1.20 | $1.24 | $1.195 | $1.22 | 579.88K |
| Jul 22, 2026 | $1.24 | $1.285 | $1.21 | $1.24 | 787.17K |
| Jul 21, 2026 | $1.24 | $1.30 | $1.24 | $1.27 | 861.18K |
| Jul 20, 2026 | $1.33 | $1.40 | $1.26 | $1.26 | 659.55K |
The latest Smart Investors Daily articles mentioning ADCT.
ADCT research
Company profile and research snapshot.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 4, 2026 | RBC Capital | Sector Perform | — |
| May 5, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Jun 30, 2026
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamabFull data expected in fourth quarter of 2026LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT),
Fintel · Jun 30, 2026
Benzinga · Jun 24, 2026
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibilityCompany focused on delivering upcoming regulatory and clinical milestones,
Fintel · Jun 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADCT.
